Abstract:Abstract Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor, characterized by a poorly accessible microenvironment that render it notoriously hard to treat. The insufficient treatment success is, in large parts, due to its tremendous molecular heterogeneity, which affects the overall prognosis and response to therapies. The significant intra- and inter-tumor microenvironment (TME) composition heterogeneity plays a crucial role in GBM progression. Mostly due to this high, multifactorial immunosuppression occurring in the microenvironment, the efficacy of immunotherapy in GBM is low. Focusing on characterizing the components of different TMEs to evaluate their molecular and cellular component heterogeneity has a significant advantage to target group of cancer patients that would normally be resistant to immunotherapy. Methods: Deep spatial transcriptomics profiling was performed on non-treated glioblastoma human tissue microarrays (TMA) using NanoString's GeoMx Digital Spatial Profiler (DSP). 6 tumor tissues from 6 different patients were hybridized and analyzed with the Whole Transcriptomic Atlas (WTA) panel that includes 18,000 genes. Three regions of interest (ROIs) were selected per tissue sample. All the statistical analysis were performed with GeoMx® DSP Analysis Suite. Cell deconvolution using the SpatialDecon® algorithm (Nanostring®) was then performed to estimate mixed cell type abundance in the spatially-resolved gene expression defined segments. Results: Spatial transcriptomic analyses revealed that glioblastoma tumors varied dramatically in their global gene expression profiles and suggested the existence of differential gene expression among the tumors highlighting the inter-tumors heterogeneity of glioblastoma. Interestingly, different areas of the same tumor did not display distinct molecular profiles. Upregulation of stromal collagen genes was significantly detected in some patient specifically the fibrillar collagens type I, III and VI. Those findings indicated excessive collagen depositions in the surrounding of the tumor for some patient characteristic of tumor progression and involvement of cancer associated fibroblasts (CAFs) in the dysregulated collagen turnover leading to tumor fibrosis. Conclusion: As a cold tumor, malignant glioma has strong immunosuppression and immune escape characteristics. The TME provides the “soil” for the survival of malignant tumors, and recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumors in the TME. Here the spatial transcriptomic analyses allowed a better phenotypical stratification of the cancer patient. In some, targeting CAFs would improve the TME and enhance the efficacy of immunotherapy. Citation Format: Sandra Delebecq, Adele Ponzoni, Richard Ruez, Corinne Ramos, Jonathan Stauber. Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4629.

Abstract 4596: BIOhabitats clinical study (NCT05375318): Histopathological analysis of vascular habitats in glioblastoma defined by perfusion MRI

Abstract 4258: Preliminarily results of the Oncohabitats Study: A multicentre validation of overall survival (OS) estimation of patients with glioblastoma (GBM) using vascular biomarkers

P15.02.B Spatial habitat analysis in high-grade gliomas combining perfusion, diffusion, and hypoxia features derived from multiparametric MRI and 18F-FAZA PET

TMIC-82. SPATIAL AND SINGLE-CELL PROTEOMIC LANDSCAPING OF THE HYPOXIC MICROENVIRONMENT IN GLIOBLASTOMA

Mapping Tumor Habitats in IDH-Wild Type Glioblastoma: Integrating MR Imaging, Pathologic, and RNA Data from Ivy Glioblastoma Atlas Project

Prospective Longitudinal Analysis of Physiologic MRI-based Tumor Habitat Predicts Short-term Patient Outcomes in IDH-wildtype Glioblastoma

Biom-18. Mapping Tumor Habitats In Idh-Wild Type Glioblastoma: Integrating Mr Imaging, Pathologic, And Rna Data From Ivy Glioblastoma Atlas Project

Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.

Metabolic Habitat Imaging with Hemodynamic Heterogeneity Predicts Individual Progression-free Survival in High-grade Glioma

Biom-40. Blood And Nasal Biomarkers Of Brain Microenvironment Blood–Brain Barrier Permeability: Clinical And Applied Concepts

Abstract 3763: Comparative spatial analyses of the tumor immune landscape in different mouse models of glioblastoma

Abstract 4629: Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies

Abstract 5474: Combined use of MRI and TAM analysis in GB monitoring

Tmic-80. High-Dimensional Histopathologic Evaluation Of The Hypoxic Tumor Microenvironment In Glioblastoma

Abstract 6171: Evolution of the spatial myeloid-lymphoid engagement in glioblastoma under temozolomide treatment

Abstract 5666: Exploring spatially resolved intra-tumoral heterogeneity of glioblastoma and neuronal mechanisms facilitating brain invasion

P02.11.B An hypothesis generating study of MRI-Derived Radiomics on tumor and microenvironment tissue heterogeneity to guide post-operative management of glioblastoma: toward personalized radiation treatment volume delineation

Abstract 1151: Reconstruction of the spatial ecosystem of glioblastoma reveals relationships between tumor cell states and microenvironment

116 Deep high-plex spatial phenotyping of glioblastoma multiforme provides new insights into the immune landscape and tumor heterogeneity

OS09.5.A BREAKING DOWN BARRIERS: THE IMPACT OF BLOOD-BRAIN BARRIER DISRUPTION ON THE GLIOMA METABOLIC MICROENVIRONMENT, IN SITU

Abstract 5980: Identification of pre-treatment tumor habitats for the prediction of neoadjuvant therapy response in triple negative breast cancer